Home

Otonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. This field represents a large opportunity as there are no approved drug treatments for the nearly 30 million Americans facing debilitating hearing and balance disorders such as Ménière's disease, sudden sensorineural hearing loss, noise-induced hearing loss, age-related hearing impairment, and tinnitus. Additionally, new therapies are required for otitis media since resistance to oral antibiotics is increasing and short-acting locally administered drugs present significant compliance challenges. Otonomy is working in partnership with leading experts in the field of otology to bring new drug therapies to patients suffering with these conditions.

 

Mar 20, 2014 Otonomy Appoints Vickie Capps to Board of Directors
   
Feb 25, 2014 Otonomy Appoints Robert Savel as Chief Technical Officer
   
Dec 11, 2013 Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Ménière's Disease
   
Dec 11, 2013 Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
   
Oct 31, 2013 Otonomy Acquires Assets and Patent Rights for Tinnitus Program
   
Sep 04, 2013 Otonomy Completes $45.9 Million Series C Equity Financing
   
Aug 20, 2013 Otonomy Announces Positive Phase 1b Results for OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
   
Sep 29, 2011 Otonomy Presents Positive New Findings from Phase 1b Study of OTO-104 in Ménière's Disease at International Conference
   
Jun 8, 2011 Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure
   
May 25, 2011 Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
   
Apr 28, 2011 Otonomy Announces Positive Results from Phase 1b Study of OTO-104 in Ménière's Disease
   
Feb 22, 2011 Otonomy’s OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
   
Dec 8, 2010 Otonomy Appoints David A. Weber, Ph.D., CEO
 
Aug 30, 2010 Otonomy Closes $38.5 Million Series B Financing
 
Jun 11, 2010 Otonomy Closes $10 Million Series A Financing
 
May 3, 2010 Otonomy Presents Data on Breakthrough Ear Treatment
 
 

COPYRIGHT AND TRADEMARK NOTICES
All contents of this Website are © 2013 Otonomy, Inc.  All rights reserved.  The OTONOMY® mark is a registered trademark of Otonomy, Inc. 
The Otonomy logo, OTO-104, and OTO-201 are trademarks of Otonomy, Inc. 

new